Cardiology

End stage kidney disease

Questions discussed in this category

What is your approach to initiating spironolactone in patients with end stage kidney disease and heart failure?

4 Answers available

How would you approach the timing of hemodialysis for an ESKD patient with no urgent indications who has NSTEMI with a troponin level of 10 ng/dl, has not had dialysis in 2 days, and is planned for left heart catheterization the next day?

1 Answer available

Do you recommend avoiding ESAs in ESKD patients with heart failure who require a left ventricular assist device?

1 Answer available

For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?

1 Answer available

Should CT coronary calcium score be avoided in dialysis patients in light of presumed high prevalence of CAC in this population?

3 Answers available

Do you recommend continuing SGLT2 inhibitors in patients with diabetic kidney disease and congestive heart failure who have been taking the medication for several years and later develop end stage kidney disease?

3 Answers available

Papers discussed in this category

The New England journal of medicine, 2015 Sep 17

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

The New England journal of medicine, 2020 Sep 24

Dapagliflozin in Patients with Chronic Kidney Disease.

Kidney international, 2019-04

Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.

Kidney360, 2023 Feb 10

Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial.

Frontiers in medicine, 2022 Mar 17

Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials.

The international journal of cardiovascular imaging, 2021 Feb 05

The effect of spironolactone on diastolic function in haemodialysis patients.

The New England journal of medicine, 2014-09-11

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Circulation, 2022 Apr 01

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

The New England journal of medicine, 2019 Sep 19

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

The New England journal of medicine, 2020 Aug 28

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Related Topics in Cardiology